Reuters quotes from Berman Tabacco attorney Stephen Ryan, Jr.’s argument at the March 20, 2019 hearing on defendants’ motion to dismiss the whistleblower lawsuit U.S. ex rel Clarke, et al. v. Aegerion Pharmaceuticals Inc, et al., No. 13-cv-11785 (D. Mass.). See Nate Raymond, Ex-Aegerion execs, employees seek to escape drug marketing case, Reuters (Mar. 21, 2019), https://www.reuters.com/article/health-aegerion-idUSL1N21809V. The Firm represents the whistleblowers alleging that defendants marketed the cholesterol drug Juxtapid for off-label purposes and submitted false claims to government agencies such as Medicare and Medicaid in connection with sales of this drug.